Eruptive warty dyskeratomas on the trunk of a man with end‐stage renal disease

Abstract

Recently, two similar cases of ENL successfully treated with apremilast were reported (Table 1). 5 Three patients failed classic therapies and improved in less than 4 weeks with apremilast, without any relevant side effect. A safe side effect profile, a lack of strong immunosuppressive activity, an oral administration, and no requirement for routine laboratory monitoring are some of the features that support apremilast as a great value drug for many difficult-to-treat inflammatory dermatoses, including ENL.